Epilepsy, Generalized Cochrane Pediatric Emergency Medicine Reviews
Browse Cochrane Pediatric Emergency Medicine Reviews
Browse Cochrane Pediatric Emergency Medicine Reviews
Cochrane Systematic Review: Lamotrigine versus carbamazepine monotherapy for epilepsy
Cochrane Systematic Review: Lamotrigine versus carbamazepine monotherapy for epilepsy
- Visit
Gamble CL, Williamson PR, Marson AG
Gamble CL, Williamson PR, Marson AG
OBJECTIVES: To review the best evidence comparing carbamazepine and lamotrigine when used as monotherapy in people with partial onset seizures, or generalized onset tonic-clonic seizures with or without other generalized seizure types.
OBJECTIVES: To review the best evidence comparing carbamazepine and lamotrigine when used as monotherapy in people with partial onset seizures, or generalized onset tonic-clonic seizures with or without other generalized seizure types.
Cochrane Systematic Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy
Cochrane Systematic Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy
- Visit
Tudur Smith C, Marson AG, Williamson PR
Tudur Smith C, Marson AG, Williamson PR
OBJECTIVES: To review the effects of carbamazepine compared to phenobarbitone monotherapy for people with partial onset seizures or generalized onset tonic-clonic seizures.
OBJECTIVES: To review the effects of carbamazepine compared to phenobarbitone monotherapy for people with partial onset seizures or generalized onset tonic-clonic seizures.
Cochrane Systematic Review: Treatment of Lennox-Gastaut syndrome
Cochrane Systematic Review: Treatment of Lennox-Gastaut syndrome
- Visit
Hancock EC, Cross JH
Hancock EC, Cross JH
OBJECTIVES: To compare the effects of pharmaceutical therapies used to treat LGS in terms of control of seizures and adverse effects. Many people who suffer from this syndrome will already be receiving other antiepileptic medications at the time of their entry into a trial. However, for the purpose of this review we will only consider the effect of the single therapeutic agent being trialled (often as add-on therapy).
OBJECTIVES: To compare the effects of pharmaceutical therapies used to treat LGS in terms of control of seizures and adverse effects. Many people who suffer from this syndrome will already be receiving other antiepileptic medications at the time of their entry into a trial. However, for the purpose of this review we will only consider the effect of the single therapeutic agent being trialled (often as add-on therapy).
Cochrane Systematic Review: Lamotrigine versus carbamazepine monotherapy for epilepsy
Cochrane Systematic Review: Lamotrigine versus carbamazepine monotherapy for epilepsy
- Visit
Gamble CL, Williamson PR, Marson AG
Gamble CL, Williamson PR, Marson AG
OBJECTIVES: To review the best evidence comparing carbamazepine and lamotrigine when used as monotherapy in people with partial onset seizures, or generalized onset tonic-clonic seizures with or without other generalized seizure types.
OBJECTIVES: To review the best evidence comparing carbamazepine and lamotrigine when used as monotherapy in people with partial onset seizures, or generalized onset tonic-clonic seizures with or without other generalized seizure types.
Cochrane Systematic Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy
Cochrane Systematic Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy
- Visit
Tudur Smith C, Marson AG, Williamson PR
Tudur Smith C, Marson AG, Williamson PR
OBJECTIVES: To review the effects of carbamazepine compared to phenobarbitone monotherapy for people with partial onset seizures or generalized onset tonic-clonic seizures.
OBJECTIVES: To review the effects of carbamazepine compared to phenobarbitone monotherapy for people with partial onset seizures or generalized onset tonic-clonic seizures.
Cochrane Systematic Review: Treatment of Lennox-Gastaut syndrome
Cochrane Systematic Review: Treatment of Lennox-Gastaut syndrome
- Visit
Hancock EC, Cross JH
Hancock EC, Cross JH
OBJECTIVES: To compare the effects of pharmaceutical therapies used to treat LGS in terms of control of seizures and adverse effects. Many people who suffer from this syndrome will already be receiving other antiepileptic medications at the time of their entry into a trial. However, for the purpose of this review we will only consider the effect of the single therapeutic agent being trialled (often as add-on therapy).
OBJECTIVES: To compare the effects of pharmaceutical therapies used to treat LGS in terms of control of seizures and adverse effects. Many people who suffer from this syndrome will already be receiving other antiepileptic medications at the time of their entry into a trial. However, for the purpose of this review we will only consider the effect of the single therapeutic agent being trialled (often as add-on therapy).
